Latest Insider Transactions at Cellectar Biosciences, Inc. (CLRB)
This section provides a real-time view of insider transactions for Cellectar Biosciences, Inc. (CLRB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cellectar Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cellectar Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2023
|
Andrei Shustov Senior Vice President, Medical |
BUY
Grant, award, or other acquisition
|
Direct |
47,856
+46.51%
|
-
|
|
Dec 08
2023
|
Chad J Kolean Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,554
+49.99%
|
-
|
|
Dec 08
2023
|
Darrell Shane Lea Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,599
+50.0%
|
-
|
|
Dec 08
2023
|
James V Caruso President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,596
+45.19%
|
-
|
|
Dec 08
2023
|
Jarrod Longcor Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,927
+44.68%
|
-
|
|
Sep 14
2021
|
Douglas J Swirsky Director |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$25,000
$1.04 P/Share
|
|
Sep 03
2021
|
Frederick W Driscoll Director |
BUY
Open market or private purchase
|
Direct |
19,417
+50.0%
|
$19,417
$1.04 P/Share
|
|
Mar 04
2021
|
James V Caruso President and CEO |
BUY
Open market or private purchase
|
Direct |
5,100
+5.57%
|
$5,100
$1.7 P/Share
|
|
Dec 28
2020
|
Dov Elefant Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,407
+38.65%
|
$7,407
$1.35 P/Share
|
|
Dec 28
2020
|
Jarrod Longcor Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
29,630
+22.48%
|
$29,630
$1.35 P/Share
|
|
Dec 28
2020
|
James V Caruso President and CEO |
BUY
Open market or private purchase
|
Direct |
37,037
+31.3%
|
$37,037
$1.35 P/Share
|